Utilization of CRISPR Interference to Validate MmpL3 as a Drug Target in Mycobacterium Tuberculosis.
Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.00629-19
Full Text
Open PDFAbstract
Available in full text
Date
June 3, 2019
Authors
Publisher
American Society for Microbiology